Harrow obtains J-code for ocular surface anesthesia gel
Click Here to Manage Email Alerts
CMS issued a permanent, product-specific J-code for Iheezo, an ocular surface anesthesia gel, according to a Harrow press release.
The code, J2403, goes into effect April 1.
Source: Adobe Stock.
Iheezo is a single-patient-use ophthalmic gel preparation of chloroprocaine hydrochloride approved by the FDA in September 2022. Clinical trials showed that participants treated with Iheezo did not require supplemental treatment to complete surgical procedures, according to the release.
“We are committed to the accessibility of new therapies that benefit eye care professionals and the patients they serve,” Mark L. Baum, Harrow chairman and CEO, said in the release. “As we prepare for the commercial launch of Iheezo in the coming months, we are grateful that Iheezo will have its own permanent, product-specific J-code beginning April 1, 2023, enabling a more efficient billing process for ophthalmologists, optometrists and retina specialists, and creating greater accessibility to the many clinical benefits that Iheezo provides.”
Read more about
Click Here to Manage Email Alerts